1. The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. PARP and PARP Inhibition

5. PARP Inhibitors Studied in Breast Cancer

6. BROCADE 2: Study Design

7. BROCADE 2: Results

8. I-SPY2: Veliparib/Carboplatin Graduates

9. BrighTNess: TNBC and Continuous Dosing

10. BrighTNess Efficacy Data

11. Phase 2 Studies of Olaparib in gBRCA+ MBC

12. ABRAZO: Talazoparib Phase 2 in gBRCA+ MBC

13. OlympiAD Study Design

14. Primary Endpoint: PFS by BICR

15. Time to Second Progression or Death (PFS2) by Investigator Assessment

16. OS: Interim Analysis (46% Data Maturity)

17. Objective Response by BICR

18. ORRs in Subgroups

19. OlympiA Study Population

20. OlympiA: Methodology

21. Pilot Study of Neoadjuvant Talazoparib For Early-Stage BRCA+ Breast Cancer

22. Pilot Study of Neoadjuvant Talazoparib For Early-Stage BRCA+ Breast Cancer (cont)

23. OlympiAD: AEs

24. OlympiAD: AEs (cont)

25. Ongoing Questions

26. Assays for “BRCAness”/HRD

27. Mechanisms of Resistance to PARP Inhibitors

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)